Barry Keith Herman, M.D., M.M.M.

Addresses

Sunovion Pharmaceuticals, Inc.

84 Waterford Drive Marlborough, MA 01752 USA Direct: 508-357-7450 FAX: 508-357-7865 E-mail: Barry.Herman@sunovion.com

Home Office

277 Upper Gulph Road Radnor, PA 19087 USA Telephone: (610) 687-4354 E-mail: RockDoc50@aol.com

Professional Experience

Sunovion Pharmaceuticals, Inc.

Clinical Research and Medical Affairs Marlborough, MA July 2010-present

Executive Medical Director, Group Leader, Area Medical Specialists: Lead a

neuroscience field-based medical team (Area Medical Specialists) to provide medical support for Latuda® (lurasidone HCI). Develop and oversee strategic operating plan to support medical affairs and to ensure alignment with the commercial enterprise. Collaborate with and support internal functional areas including brand clinical research and medical affairs, health economics/outcomes research, organized customer group, medical information government affairs, and compliance. Manage operating budget to support the line function. Develop, train, and retain talent.

Sanofi-aventis, U.S. Medical Affairs Organization

Bridgewater, NJ Jan 2009-July 2010

Area Medical Officer: Area Chief Medical Officer of one of six Sanofi-aventis U.S. regional business units (Mid-Atlantic). Regional responsibility for the coordination of medial affairs activities and interface between US Medical Affairs Organization (USMAO) line functions (Evidence Based Medicine, Drug Safety, Independent Medical Education, Medical Operations, Regulatory, Regional Medical Liaisons), Area commercial operations and related support functions for 9 states.

Barry K. Herman, M.D. Professional Experience Continued

Pfizer, Inc. Pfizer Global Pharmaceuticals

Philadelphia, PA and New York City, NY July, 2001-Jan, 2009

Senior Medical Director. Global Medical Division. LYRICA® Product Team. New York City. NY, Jan 2008-Jan 2009: Product team senior medical director. Provided worldwide medical support for the Lyrica (pregabalin) clinical program and life cycle management for generalized anxiety disorder and fibromyalgia indications. Chair, Grants Review Committee, Psychiatry Disease Area Work Group and Publications Work Group. Team lead for Managed Markets Work Group; Promotional Review Committee. Senior Regional Medical Director, US Medical Neurosciences, Philadelphia, PA, July, 2001-Jan 2008: Fieldbased, senior regional medical director (RMRS group). Provided medical solutions to deliver regional business impact through clinical research and scientific communications with national thought leaders and key academic institutions and business accounts. Collaborated with global medical teams and with divisions across Pfizer to execute business strategies to support entire CNS portfolio through product life cycles. Member of product team grants, publications, and medical subcommittees. Member, national group operating plan committee, 2004. Presented national RMRS operating plan, 2004. Mid-Atlantic Regional Medical Council Coordinator (RMCC) and representative to regional sales council (2004-2006). Pfizer Values in Action Award (Innovation) 2003; RMRS Outstanding Achievement Awards (2004, 2006); RMRS Achievement Award (Innovation) 2007.

Barry K. Herman, M.D., & Associates, P.A. (A Professional Corporation)

Austin, Texas, Amarillo Texas, and Philadelphia, Pennsylvania June 2002-2005 (Philadelphia); October 1989-June 2002 (Austin); October 1999-November 2000 (Austin and Amarillo)

President and Chief Executive Officer: Private practice of child, adolescent and adult psychiatry; forensic psychiatry; contract utilization review; and behavioral healthcare systems consultation.

United Healthcare of Texas, Inc.

Corpus Christi, Texas

August 1998-June 1999

Medical Director: Medical Director of an open-access, mixed model HMO with 30,000 enrolled members and approximately 1,400 physician network providers covering 22 counties in South Texas. Responsibilities included reorganization and oversight of the health services department; medical utilization and quality management; credentialing; provider contracting; clinical profiling; disease management program development; committee support; provider network management; NCQA survey preparation. 15 direct reports. United "Medical Excellence Award" 1999 for Responsibility and Accountability. Did not accept a relocation offer when the plan was consolidated. Barry K. Herman, M.D. Professional Experience Continued

FIRSTCARE Southwest Health Alliances

Austin, Texas April, 1996-April 1998 Vice President, Corporate and Regional Medical Director, Interim Regional Executive Director.

Vice President and Corporate Medical Director (4/96-4/98) of a Texas, hospital-owned, network model HMO with over 100,000 enrolled members (9,000 Medicaid members) and over 2,000 network physician providers in four large geographic regions (greater than 100 counties). **Regional Medical Director** of Amarillo Regional Plan (4/96-6/97) with 50,000 enrolled members and over 450 network physician providers. **Interim Regional Executive Director** of Amarillo Plan (3/1-9/1/97). Requested and received a retention agreement when it appeared that the health plan would sell.

Key Responsibilities:

- Corporate Medical Director: Liaison to plan regional medical directors; Physician profiling; Medical management policies and procedures; Medical Advisory and Medical Technology Assessment Committees; Corporate provider credentialing oversight; Oversight of behavioral health care vendor relationship.
- Regional Medical Director: Utilization Management; Credentialing; Quality Management; Physician Committee Support; Provider Network Management; NCQA Survey Preparation.
- Interim Regional Executive Director: Plan Operations; Contracting; Marketing; Public Relations. 35 direct reports.

Capital Area PsySystems, Inc. (dba Capital Area Psych Services, Integrated Mental Health Services)

Austin, Texas

September, 1992- January 1995

Chief Executive Officer and Medical Director. Founded a staff model, multidisciplinary behavioral health care clinic with over 15 full-time equivalent practitioner employees and three practice locations. Responsible for clinical oversight and supervision of program and staff; strategic business planning; development of medical utilization policies and procedures and case management system; clinical program development; contract negotiations; marketing. First national group practice acquisition by GPA, Inc., a subsidiary of Magellan Health.

Charter Hospital of Austin

Austin, Texas

September, 1989- June, 1991

Medical Director. Medical Director of a 108-bed, full-service, freestanding psychiatric hospital. Served on and/or chaired all hospital committees including Quality Assurance, Pharmacy and Therapeutics, Infection Control, Credentialing, Peer Review. Took hospital through successful surveys by JCAHO and HCFA. Developed a continuing medical education program for medical staff.

Barry K. Herman, M.D. Professional Experience Continued

Greenleaf Center, Inc.

Jonesboro, Arkansas April, 1987- June 1989

Medical Director, Child and Adolescent Services. Medical Director of a 14-bed adolescent inpatient psychiatric program. Responsible for the overall development and clinical supervision of the program.

The Children's Clinic/Child and Youth Development Center

Jonesboro, Arkansas August, 1985- June 1989

Child Psychiatry and Primary Care Medicine. National Health Service Corps Scholarship service obligation. Helped to develop a multidisciplinary, staff model outpatient child development clinic in association with a private pediatric practice. Received service commendation letter from Surgeon General C. Everett Koop.

Education

Tulane University/School of Public Health and Tropical Medicine (New Orleans, Louisiana) M.M.M. (Masters of Medical Management Degree), 1998

Stanford University School of Medicine, Children's Hospital at Stanford (Palo Alto, California)

Fellowship in Child and Adolescent Psychiatry, 1983-85

Herrick Hospital and Health Center

(Berkeley, California)

Residency in Psychiatry, 1981-83 (Chief Resident, 1982-83)

Santa Barbara Cottage Hospital & Clinics

Affiliated with the University of Southern California School of Medicine (Santa Barbara, California)

Residency in Internal Medicine, 1980-81

Tufts University School of Medicine (Boston, Massachusetts) M.D. 1980

University of Southern California (Los Angeles, California) Post-undergraduate study (non-degree Pre-Med), 1973-76

Clark University (Worcester, Massachusetts) B.A. (Psychology) 1974

Certifications

Diplomate in Psychiatry #27812 (1986), American Board of Psychiatry and Neurology (ABPN) Diplomate in Child and Adolescent Psychiatry #2189 (1987), ABPN **Certified Physician Executive** (1998), The Certifying Commission in Medical Management **Diplomate**, (1997), Graduate Program in Medical Management, American College of Physician Executives

Organizations

Distinguished Fellow, American Psychiatric Association, Pennsylvania Psychiatric Society, & Philadelphia Psychiatric Society (1994); (Member, 1983)

Lifetime Vanguard Fellow Emeritus, American College of Physician Executives (1989) Fellow, American Academy of Child and Adolescent Psychiatry (1991); (Member 1985) Life Member, American Medical Association & Member, Pennsylvania Medical Society and Delaware Co. Medical Society

Member, American Association of Psychiatric Administrators (President, 2011-2013) **Member**, American Association of Practicing Psychiatrists (2001-) Board of Directors (2008-)

Affiliate Member, Texas Medical Association (2002-) Active Member (1989-2002) Affiliate Member, American Psychoanalytic Association (2008-)

Academic Appointments

- Senior Scholar (non-affiliate faculty), Jefferson School of Population Health, Thomas Jefferson University, (2005-)
- Clinical Assistant Professor, Department of Psychiatry, Texas Tech University Health Sciences Center (2000-2001)
- Clinical Faculty, Austin State Hospital Psychiatric Residency Program (1990-2002)
- Associate Clinical Faculty, University of Arkansas Medical Sciences Center, Department of Psychiatry (1987-89).
- Founding and Charter Member, Center for the Advanced Study of the Psychoses, San Francisco, CA (1983-85)

Appointments

- Editorial Board, Journal of Psychiatric Administration and Management (2011-)
- APA Association of Allied Organizations Liaison (AAOL) Assembly Representative, American Assoc. of Psychiatric Administrators (2005-)
- American Psychiatric Association: Legislative Affairs Representative from the Texas Society of Psychiatric Physicians (TSPP) to APA Division of Government Relations (1995-97); Managed Care Committee, (2005-2008); Audit Committee (2006-2009); Ad Hoc Work Group, Industry Relations (2006); Committee on Business Relations (2007-2008); Corresponding Committee on Ethics in Research (2008-); Budget and Finance Committee (2009-)
- American Association of Psychiatric Administrators, Board of Directors (2004-) Treasurer (2007-2009); President-elect (2009-2011); President (2011-)
- The American College of Physician Executives, Council of Fellows (2008-) (Chair, 2010-11)
- The Irwin Foundation, Board of Directors (2008-)
- American Association of Practicing Psychiatrists, Board of Directors (2008-)

Barry K. Herman, M.D. Appointments Continued

- The National Coalition of Mental Health Professionals & Consumers, Inc, Executive Board, (2001-2002)
- American Academy of Child & Adolescent Psychiatry, Research Forum Founders (2003-2009) and Pediatric Psychopharmacology Initiative (2003-2009)
- Chair, CME Course in Administrative Psychiatry, APA (Annual Meeting and IPS); 2007-2011
- Jefferson CME-Industry Council, Office of Continuing Medical Education of Jefferson Medical College, Charter Member (2002-2005)
- American Board of Psychiatry and Neurology, Examiner (1994-)
- Texas Medical Association from Travis County Medical Society, Alternate Delegate and Delegate (1996-2002)
- Pennsylvania Medical Society, Alternate Delegate (2007-)
- Delaware County (PA) Medical Society, Board of Directors (2007-)
- Philadelphia Psych Soc., Chair, Govt. Relations Committee (2006-2008); Nominating Committee (2007)
- Editorial Review Panel, The Physician Executive, American College of Physician Executives, (2001-)
- Editorial Review Board, Journal of Managed Care Medicine, Genomics & Biotech (1998-)
- Founder, CEO and Chairman of the Board, Boyer House Foundation, San Francisco, CA (1984-93)
- Arkansas Youth Suicide Prevention Commission, appointed by Governor Bill Clinton (1987-89)

Professional Positions and Consultation

- Psychiatric Consultant, Texas Department of Criminal Justice, Program for Aggressive Mentally III Offenders (PAMIO) at the Clements Unit, Amarillo, TX, 1999-2001
- Consultant, Parkwood Hospital and Clinics, Olive Branch, MS. Provided clinical and administrative services to a rural outpatient mental health clinic system, 1996
- Medical Utilization and Facility Site Surveyor (Medicaid), First Mental Health, Inc., Nashville, TN, 1995-96
- Medical Director, Neuropsychiatric Treatment Center, CPC Capital Hospital, Austin, TX. Medical Director of a neuropsychiatric and neurodevelopmental residential treatment program for children and adolescents, 1995
- Medical Director, CPC Capital Hospital, Austin, TX. Interim Medical Director of a 130bed, free-standing psychiatric hospital, 1995
- Child Psychiatry Consultant, The Prudential, Austin, TX 1993-96
- Clinical Consultant, Boyer House Foundation, Marin County and Berkeley, CA, 1989-1992
- Child Psychiatry Consultant, New Beginnings, Austin, TX. A preventative program for atrisk adolescents and families, 1993-94
- Medical Director, Pathways at Meridell, Meridell Achievement Center, Austin, TX. A continuum of care program for children, adolescents and families, 1993
- Medical Director, New Beginning Program, The Faulkner Center, Austin, TX. A continuum of care program for children, adolescents and families, 1992-93
- Child Psychiatry Consultant, The Balcones Special Services Cooperative, Special Education Program of the Eanes Independent School District, Austin, TX, 1989-91
- Child Psychiatry Consultant, The Alternative School, Special Education Program of the Jonesboro School District, Jonesboro, AR, 1985-89

Barry K. Herman, M.D. Professional Positions and Consultation Continued

- Clinical Consultant and Research Assistant, Stanford University School of Medicine, Sleep Disorders Research Laboratory, Palo Alto, CA 1982-85
- Psychiatric Consultant, Contra Costa County Community Mental Health System, Martinez, CA 1982-85
- Laboratory Technician and Research Assistant, Microbiology and Immunology Laboratories, UCLA School of Medicine, Harbor General Hospital, Torrance, CA, 1974-76

Awards

- Physicians Recognition Award, American Medical Association (1981-present)
- Faculty Recognition Award, Austin Psychiatric Residency Program (1995)
- Distinguished Service Award, Texas Society of Child & Adolescent Psychiatry (1995)
- Certificate of Appreciation, Texas Society of Psychiatric Physicians (1996)
- United Healthcare Medical Excellence Award for Responsibility and Accountability in medical management, 1999.
- Pfizer Regional Medical & Research Specialists "Outstanding Achievement Award" for performance, (2004, 2006); Values in Action (VIA) Award for Innovation (2003); Achievement Award for Innovation (2007)
- Neuroleptic Malignant Syndrome Information Service's (NMSIS) "Corporate Partner Award," May 3, 2004, NYC

Medical Licensure

California (1981-)-active Arkansas (1985-)-active Texas (1989-)-active Mississippi (1995-)-active

Pennsylvania (2003-2008; 2009- active retired)

Book Chapters

Herman, Barry K. and Peel, Deborah C. "Federal law violates patients' privacy," *Privacy: Opposing Viewpoints Series,* Carroll, Jamuna (Ed), 2006, Thompson Gale, MI, pp 141-148

Herman BK Preface in Boyer, L. Bryce & Giovacchini, Peter L. (Eds.) 1993. Master clinicians on treating the regressed patient. Volume 2 Northvale, NJ: Jason Aronson.

Publications, Abstracts, & Letters

Campbell EC, DeJesus M, Herman BK, Cuffel BJ, Sanders KN, Dodge W, Dhopesh V, Caroff SN.

A pilot study of antipsychotic prescribing decisions for acutely-III hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):246-51

Herman, B (Editor) Special report: practice management Psychiatric Times. Vol 27 No 2 Feb 7 2010

Lydiard RB, Rickels K, Herman B, Feltner DE.

Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.

Int J Neuropsychopharmacol. 2009 Sep 9:1-13. [Epub ahead of print] PMID: 19737439

Lawson, WB, Herman, BK, Loebel, A, Lazariciu, I, and Malik, M Ziprasidone in Black Patients with Schizophrenia: Analysis of Four Short-term, Double blind Studies

CNS Spectr 14:9, September 2009

Montgomery SA, Herman BK, Schweizer E, Mandel FS The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia Int Clin Psychopharmacol. 2009, Jul;24(4): 214-22 PMID: 19542983

Stein DJ, Lydiard RB, Herman BK, Mandel FS. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis Int Clin Psychopharmacol. 2009 May;24(3):126-32. PMID: 19352198

Kasper, S, Herman, B, Nivoli, G, Van Ameringen, M, Petralia, A, Mandel, F, Baldinetti, F, and Bandelow, B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial Int Clin Psychopharmacol, 2009, 24:87–96

Stein, DJ, Mandel, FS, Szczypa, P, Schweizer, E and Herman, BK Tension in Generalized Anxiety Disorder: A Relatively Neglected Treatment Target American Psychiatric Association Annual Meeting, May 16-21, 2009, San Francisco, CA

Herman, BK and Mandel, F

Is Speed of Onset of Anti-Anxiety Efficacy with Pregabalin Influenced by Starting Dose? European Psychiatric Association Annual Meeting, January 24-28, 2009, Lisbon, Portugal

Herman, BK, Mychaskiw, MA, Mandel, F Comparison of Sleep Outcomes in Generalized Anxiety Disorder Following Treatment with Pregabalin or Venlafaxine-XR European Psychiatric Association Annual Meeting, January 24-28, 2009, Lisbon, Portugal

Campbell, EC, Herman, BK, Cuffel, BJ, Dodge, W, Dhopesh, V, O'Brien, C, Caroff, SN Metabolic Risk and Prescribing Decisions in Antipsychotic Therapy American College of Neuropsychopharmacology Annual Meeting, Dec 8, 2008, Scottsdale, AZ

Mychaskiw, M, Hoffman, D, Dodge, W, Herman, B. Psychic and Somatic Anxiety Symptom Burden and Functional Remission in Generalized Anxiety Disorder European Congress of Neuropsychopharmacology, August 30-Sept 3, 2008, Barcelona,

European Congress of Neuropsychopharmacology, August 30-Sept 3, 2008, Barcelona, Spain

Herman, B, Nivoli, G, Petralia, A, Mandel, F.

Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial

XXVI Congress of the Collegium Internationale Neuro-Psychopharmacologicum, July 13-17, 2008, Munich, Germany

Mychaskiw, M, Alvir, J, Herman, B.

Functional and Quality of Life Impairment in Generalized Anxiety Disorder: Effect of Short-Term Treatment With Pregabalin and Venlafaxine-XR

XXVI Congress of the Collegium Internationale Neuro-Psychopharmacologicum, July 13-17, 2008, Munich, Germany

Pallanti, S, Giordano, S, Mandel, F, Herman, B. Insomnia and Generalized Anxiety Disorder: Impact on Clinical Presentation and Response to Pregabalin 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Leon, T, Whalen, E, Arnold, L, Pauer, L, Barrett, J, Herman, B. Pregabalin Improves Pain in Fibromyalgia (FM) Patients Regardless of Baseline Anxiety and Depression Levels 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Murphy, T, Nutt, D, Mandel, F, Herman, B. Rapid Onset Anxiolytic Efficacy After a Single Dose of Pregabalin: Double-Blind, Placebo-Controlled Evaluation Using a Dental Anxiety Model 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Leon, T, Pauer, L, Whalen, E, Herman, B, Barrett, J. Efficacy of Pregabalin Monotherapy for Improving Sleep Outcomes in Patients With Fibromyalgia: Results of a 14-Week, Double-Blind, Placebo-Controlled Trial (RELIEF Study) 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Andréewitch, S, Murphy, T, Petralia, A, Mandel, F, Herman, B. Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Leon, T, Pauer, L, Whalen, E, Herman, B, Barrett, J.

Efficacy of Pregabalin Monotherapy for Improving Sleep Outcomes in Patients With Fibromyalgia: Results of a 14-Week, Double-Blind, Placebo-Controlled Trial (RELIEF Study) 16th AEP European Congress of Psychiatry, 5-9 April 2008, Nice, France

Herman, BK

Managing up: dynamic following in an organizational setting. Physician Exec. 2008 Jan-Feb;34(1):46-9.

Allen, M, Vanderburg, D, Loebel, T, Herman, B, Mandel, F. Efficacy of Ziprasidone in Hospitalized Manic Patients With High Baseline Symptom Severity 59th Institute on Psychiatric Services, Oct 11 – Oct 14, 2007 New Orleans, Louisiana

Herman, BK Managing Up: Dynamic Following in an Organizational Setting Psychiatrist Administrator, 2007, 7 (2): 34-38

Gandelman, K, Miceli, J. Alderman, J., Glue, P, Versavel, M, Lombardo, I, Wilner, K, Herman, B, Preskorn, S.

The Influence of Meal Size and Fat Content on Oral Ziprasidone Bioavailability 7th International Congress on Bipolar Disorder, June 7-9, 2007, Pittsburgh, PA.

Loebel, A, Lombardo, I, Siu, C, Allison, D, Herman, B. Effect of Regression to the Mean on the Assessment of Antipsychotic-Induced Weight Gain

Society of Biological Psychiatry, May 18, 2007, San Diego, CA

Vanderburg, D, Loebel, A, Warrington, L, Herman, B, Yang, R. Ziprasidone in Hospitalized Patients with Schizophrenia: Evidence for Rapid Dose Titration 11th International Congress on Schizophrenia Research, March 28-April 1, 2007, Colorado Springs, CO

Clary C, Loebel A, Lombardo I, Alphs L, Binneman B, Vanderburg D, Warrington L, Parsons B, Fogel I, Herman B, Roberts H, Templeton H, Hughes D, Chappell P, Feltner D, Tobias K, Watsky E, Ramey T, Rappard F.

Comments on "Presidential address: advocacy as leadership". Am J Psychiatry. 2007 Feb;164(2):346; author reply 346. PMID: 17267802 [PubMed - indexed for MEDLINE]

Sacchetti, E, Galluzzo, A, Romeo, F, Gorini, B, Herman, B, Jina, A, Warrington, L. Long-term Efficacy of Ziprasidone in Treatment-Resistant Schizophrenia: Results From the 1-Year, Open-Label MOZART Extension Study 11th International Congress on Schizophrenia Research, March 28-April 1, 2007, Colorado Springs, CO

Herman, B, Sorensen, S, Cuffel, B, Lombardo, I, Revicki, D. Risk for Diabetes and Coronary Heart Disease: Effects of Metabolic Changes in Phase 1 of the CATIE Study US Psychiatric Congress, November 15-19, 2006, New Orleans, LA

Cuffel, B, Lombardo, I, Nasrallah, H, Herman, B, Sorensen, S, Revicki, D. Risk for Diabetes and Coronary Heart Disease: Effects of Metabolic Changes in Phase 1 of the CATIE Study 58th Institute on Psychiatric Services. October 5-8, 2006, New York, NY

Sacchetti, E, Galluzzo, A, Valsecchi, P, Romeo, F, Gorini, P, Herman, B, Warrington, L. Comparative Efficacy and Safety of Ziprasidone and Clozapine in Treatment-Refractory Schizophrenia: Results of a Randomized, Double-Blind, 18-Week Trial 58th Institute on Psychiatric Services. October 5-8, 2006, New York, NY

Herman, BK, Fegert, JM, Baron, D. Partnering with the pharmaceutical industry Turkish Journal of Psychiatry. 2006; 17:2: Suppl: 157-8

Lazarus, A, Herman B An overlooked group: giving pharmaceutical doc-execs their due respect Modern Physician 2006 June 9

Meyer, J, Loebel, A, Herman, B, Nasrallah, H Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia Poster presented at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, June 13 2006

Walker JK, Herman BK, Loebel A Comments on "dose response and dose equivalence of antipsychotics" in JClinPsych 2004; 24:192-208. J Clin Psychopharmacol. 2005 Oct;25(5):503-4

Citrome, L, Brook, S, Herman, BK, Loebel, A, Mandel, F Ziprasidone vs haloperidol for the treatment of agitation Society for Biological Psychiatry, May 2005, Atlanta, GA

Citrome, L, Brook, S, Herman, BK, Loebel, A, Mandel, F Ziprasidone vs haloperidol for the treatment of agitation American Psychiatric Association Annual Meeting, May 2005, Atlanta, GA

Weiden, PJ, Herman, BK, Yang, R, Lebovitz, H Course of weight and metabolic benefits 1 year after switching to ziprasidone U.S. Psychiatric Congress, San Diego, Nov 17-20 2004

Herman BK, Peel DC Point-counterpoint. HIPAA's real effect: the end of medical privacy. A new dilemma for physician executives. *Physician Exec*. 2004 Jan-Feb;30(1):34, 36-8.

Peele R, Kline L, Herman B Treating the mentally ill Health Aff (Millwood). 2001 Nov-Dec;20(6):313-4. PMID: 11816684 [PubMed - indexed for MEDLINE]

Herman BK Working with recruiters. Physicians sound off in CyberForums about their experiences with recruiters. *Physician Exec.* 2001 Jul-Aug;27(4):32-6. PMID: 11481889 [PubMed - indexed for MEDLINE]

Herman BK Another way to regain control. *Tex Med*. 1998 Aug;94(8):9-10 PMID: 9709548 [PubMed - indexed for MEDLINE]

Seidel WF, Cohen SA, Bliwise NG, Herman B, Dement WC Triazolam used to treat jet lag: dose and direction effects in a questionnaire study *Sleep Research* 1987; 16: 144.